Filtered By:
Drug: Activase

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Unequal Access to Treatment With Intravenous Alteplase for Women With Acute Ischemic Stroke Brief Reports
Conclusions— Fewer women present themselves within 4 hours from stroke onset than men and consequently less often receive thrombolytic treatment. This difference may be caused by the older age of women on average and consequently women more often living alone. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN20405426.
Source: Stroke - August 26, 2013 Category: Neurology Authors: de Ridder, I., Dirks, M., Niessen, L., Dippel, D., on behalf of the PRACTISE Investigators Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Brief Reports Source Type: research

Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months.
Conclusions. In this single centre series, bolus-infusion delays of alteplase in AIS were common and no effect of bolus-infusion delays on independence and mortality was found. PMID: 24876988 [PubMed]
Source: Stroke Research and Treatment - December 2, 2014 Category: Neurology Tags: Stroke Res Treat Source Type: research

Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients Brief Reports
Conclusions— Intravenous tirofiban immediately after alteplase seems to be safe and potentially more effective when compared with alteplase alone for selected stroke patients. Clinical Trial Registration— URL: http://www.chictr.org.cn/. Unique identifier: ChiCTR-TRC-14004630.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Li, W., Lin, L., Zhang, M., Wu, Y., Liu, C., Li, X., Huang, S., Liang, C., Wang, Y., Chen, J., Feng, W. Tags: Pharmacology, Treatment, Ischemic Stroke Brief Reports Source Type: research

Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke Clinical Sciences
Conclusions—Intravenous thrombolytics provide benefit to stroke patients with computed tomographic angiography or magnetic resonance angiography evidence of arterial obstruction, but the sample was underpowered to demonstrate significant treatment benefit or harm among patients with apparently patent arteries.Clinical Trial Registration—URL: http://www.isrctn.com. Unique identifier: ISRCTN25765518.
Source: Stroke - January 22, 2017 Category: Neurology Authors: Grant Mair, Rudiger von Kummer, Alessandro Adami, Philip M. White, Matthew E. Adams, Bernard Yan, Andrew M. Demchuk, Andrew J. Farrall, Robin J. Sellar, Eleni Sakka, Jeb Palmer, David Perry, Richard I. Lindley, Peter A.G. Sandercock, Joanna M. Wardlaw Tags: Angiography, Meta Analysis, Ischemic Stroke Original Contributions Source Type: research

Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke Clinical Sciences
Background and Purpose—Intravenous thrombolysis with alteplase is one of the few approved treatments for acute ischemic stroke; nevertheless, little is known about its long-term effects on survival and recovery because clinical trials follow-up times are limited.Methods—Patients registered between January 2005 and December 2015, to the population-based South London Stroke Register of first-ever strokes. Propensity score was used to match thrombolyzed and control cases to a 1:2 ratio by demographical and clinical covariates. The primary outcome was survival up to 10 years using Kaplan–Meier estimates, Cox proportional...
Source: Stroke - February 26, 2018 Category: Neurology Authors: Walter Muruet, Anthony Rudd, Charles D.A. Wolfe, Abdel Douiri Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions Brief Report
Conclusions—Stroke patients with DWI lesion>70 mL may benefit from reperfusion therapy, especially those with isolated M1 occlusion or ischemia restricted to the superficial middle cerebral artery territory. The benefit of treatment seems questionable for patients with carotid occlusion or lesion extending to the deep middle cerebral artery territory.
Source: Stroke - February 26, 2018 Category: Neurology Authors: Vincent Gautheron, Yu Xie, Marie Tisserand, Helene Raoult, Sebastien Soize, Olivier Naggara, Romain Bourcier, Sebastien Richard, Francis Guillemin, Serge Bracard, Catherine Oppenheim Tags: Magnetic Resonance Imaging (MRI), Prognosis, Revascularization, Quality and Outcomes, Ischemic Stroke Brief Reports Source Type: research

Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke Brief Reports
Conclusions— In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
Source: Stroke - November 23, 2015 Category: Neurology Authors: Huang, X., Moreton, F. C., Kalladka, D., Cheripelli, B. K., MacIsaac, R., Tait, R. C., Muir, K. W. Tags: Treatment, Ischemic Stroke, Thrombosis Brief Reports Source Type: research

Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis Basic Sciences
Conclusions— Our results provide the basis needed for the design of future preclinical studies on recanalization therapies using this model of thromboembolic stroke in mice. The power analysis reveals that a multicenter trial would require 123 animals per group instead of 40 for a single-center trial.
Source: Stroke - April 24, 2016 Category: Neurology Authors: Orset, C., Haelewyn, B., Allan, S. M., Ansar, S., Campos, F., Cho, T. H., Durand, A., El Amki, M., Fatar, M., Garcia-Yebenes, I., Gauberti, M., Grudzenski, S., Lizasoain, I., Lo, E., Macrez, R., Margaill, I., Maysami, S., Meairs, S., Nighoghossian, N., Or Tags: Animal Models of Human Disease, Ischemic Stroke Basic Sciences Source Type: research

Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke Brief Report
Background and Purpose—Renal dysfunction (RD) is associated with poor prognosis after stroke. We assessed the effects of RD on outcomes and interaction with low- versus standard-dose alteplase in a post hoc subgroup analysis of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study).Methods—A total of 3220 thrombolysis-eligible patients with acute ischemic stroke (mean age, 66.5 years; 37.8% women) were randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset. Six hundred and fifty-nine (19.8%) patients had moderate-to-severe R...
Source: Stroke - August 28, 2017 Category: Neurology Authors: Susan J. Carr, Xia Wang, Veronica V. Olavarria, Pablo M. Lavados, Jorge A. Rodriguez, Jong S. Kim, Tsong-Hai Lee, Richard I. Lindley, Octavio M. Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K. Sharma, Mark Woodward, John Chalmers, Craig S. Anderson, Tags: Clinical Studies, Intracranial Hemorrhage, Ischemic Stroke Brief Reports Source Type: research

Survivor gives us a lens into regional systems of care for acute ischemic stroke in North Dakota
I just got back from the North Dakota Mission: Lifeline STEMI and Acute Stroke Conference in Bismark, ND. I had a great time and I learned a lot. I often get asked to speak in various venues about acute STEMI and 12-lead ECG interpretation, but for this conference they wanted me to talk mostly about stroke. That turned out to be a good thing because it forced me to read the 2013 AHA / ASA Guildelines for the Early Management of Patients With Acute Ischemic Stroke to make sure I was asking intelligent questions during the panel discussion (which I moderated) and also giving accurate information for the class I taught about ...
Source: EMS 12-Lead - May 31, 2013 Category: Cardiology Authors: Tom Bouthillet Tags: ems-topics patient-management North Dakota Mission Lifeline Stroke Source Type: research

Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator–Treated Patients
Conclusions: Because most INS patients were found to have NNCI, which may represent either transient ischemic attack or aborted stroke, and there were no intracerebral hemorrhages in the INS group, our data support the safety of administering IV t-PA to all patients in whom acute ischemic stroke is clinically suspected. We have demonstrated that NNCI patients and stroke mimics are common, and future larger scale prospective studies are required to delineate the true frequencies of each and to evaluate differences in outcomes.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Ilana Spokoyny, Rema Raman, Karin Ernstrom, Brett C. Meyer, Thomas M. Hemmen Tags: Original Articles Source Type: research

Baseline National Institutes of Health Stroke Scale-Adjusted Time Window for Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Clinical Sciences
Conclusions— The impact of time-to-treatment on favorable outcome varies widely depending on baseline stroke severity. The window for favorable outcome was ≤120 min for moderate strokes. However, time-to-treatment seemed unrelated to functional outcome in mild and severe stroke.
Source: Stroke - March 24, 2014 Category: Neurology Authors: Muchada, M., Rubiera, M., Rodriguez-Luna, D., Pagola, J., Flores, A., Kallas, J., Sanjuan, E., Meler, P., Alvarez-Sabin, J., Ribo, M., Molina, C. A. Tags: Acute Cerebral Infarction, Thrombolysis Clinical Sciences Source Type: research

Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument
Conclusion: A simpler model using a 3-item stroke severity score, instead of the 15-item NIH Stroke Scale, has similar prognostic value and may be easier to use in routine care. Future studies are needed to test whether it can improve process and clinical outcomes.
Source: Neurology - September 14, 2015 Category: Neurology Authors: Kent, D. M., Ruthazer, R., Decker, C., Jones, P. G., Saver, J. L., Bluhmki, E., Spertus, J. A. Tags: All Cerebrovascular disease/Stroke ARTICLE Source Type: research

Lytic therapy and mechanical thrombecomty over tele-stroke, a comprehensive stroke center experience (P1.275)
Conclusions:Our study shows that our Tele stroke program had evolved over time to involve more sites throughout the state of South Carolina. Post IV tPA sICH was within the expected range.Disclosure: Dr. Al Kasab has nothing to disclose. Dr. Debenham has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Holmstedt has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kasab, S. A., Debenham, E., Jones, D. J., Holmstedt, C. A. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Results of Membrane-activated Chelator Stroke Intervention Randomized Trial of DP-b99 in Acute Ischemic Stroke Major Clinical Trials
Conclusions— Despite encouraging preclinical and phase II trial data, DP-b99 shows no evidence of efficacy in treating human ischemic stroke.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Lees, K. R., Bornstein, N., Diener, H.-C., Gorelick, P. B., Rosenberg, G., Shuaib, A., for the MACSI Investigators* Tags: Neuroprotectors Major Clinical Trials Source Type: research